A new commercial for AREXVY, a vaccine for respiratory syncytial virus, runs on TV.

“RSV can severely affect the lungs and lower airways. AREXVY is a vaccine used to prevent lower respiratory disease from RSV in people 60 years and older,” explains the voiceover in the 60-second spot, which features a diverse cast of seniors who claim they got the vaccine.

The narrator goes on by saying that RSV can be serious for those over 60, including those with asthma, diabetes, COPD and certain other conditions and that this vaccine is proven to be over 82% effective in preventing lower respiratory disease from RSV and over 94% effective in those with these health conditions. He also mentions that AREXVY does not protect everyone and is not for those with severe allergic reactions.

The most common side effects are injection site pain, fatigue, muscle pain, headache and joint pain.

Arexvy is the first respiratory syncytial virus (RSV) vaccine approved for use in the United States. The U.S. Food and Drug Administration approved it earlier this year, in May. “Today’s approval of the first RSV vaccine is an important public health achievement to prevent a disease which can be life-threatening and reflects the FDA’s continued commitment to facilitating the development of safe and effective vaccines for use in the United States,” said Peter Marks, M.D., Ph.D., director of the FDA’s Center for Biologics Evaluation and Research.